Literature DB >> 33669104

Diagnostic Value of Choline PET in the Preoperative Localization of Hyperfunctioning Parathyroid Gland(s): A Comprehensive Overview.

Cristina Ferrari1, Giulia Santo1, Paolo Mammucci1, Antonio Rosario Pisani1, Angela Sardaro2, Giuseppe Rubini1.   

Abstract

Hyperparathyroidism is a metabolic disorder characterized by the excessive production of the parathyroid hormone. The diagnosis is based on clinical and laboratory data. In most cases the only treatment is surgery and a correct preoperatory localization of the hyperfunctioning parathyroid gland(s) is essential. Currently, ultrasonography combined with [99mTc]Tc-MIBI parathyroid scintigraphy, optionally associated with single photon emission computed tomography/computed tomography (SPECT/CT), represent the standard preoperative imaging. In recent years, a number of studies have evaluated the potential role of choline positron emission tomography (PET) in hyperparathyroidism with promising results. Most of the recent evidence underlined its higher sensitivity and diagnostic accuracy in the localization of hyperfunctioning parathyroid glands. Choline PET has a higher spatial resolution that is useful for the detection of smaller parathyroid glands and it also has shorter examination times and favorable radiation exposure. These are just a few of the aspects that support it to overcome traditional imaging. Moreover, from the preliminary data, the choline uptake mechanism seems to also have an impact on its better performance. For these reasons, if first used as second level imaging in patients with negative or inconclusive traditional imaging results, several authors have supported its use as a first line investigation. This comprehensive overview aims to provide an accurate description of the preliminary results available in the literature about the use of choline PET/CT in hyperparathyroidism and to compare these results with the performance of traditional imaging methods.

Entities:  

Keywords:  PET/CT; [18F]FCH; [99mTc]Tc-MIBI; choline; hyperparathyroidism; positron emission tomography

Year:  2021        PMID: 33669104      PMCID: PMC7996619          DOI: 10.3390/biomedicines9030231

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  61 in total

1.  The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism.

Authors:  Mine Araz; Çiğdem Soydal; Elgin Özkan; Metin K Kir; Erkan İbiş; Sevim Güllü; Murat F Erdoğan; Rifat Emral; Özlem N Küçük
Journal:  Nucl Med Commun       Date:  2018-11       Impact factor: 1.690

2.  [18F]Fluorocholine Uptake of Parathyroid Adenoma Is Correlated with Parathyroid Hormone Level.

Authors:  Abdullah A Alharbi; Fahad M Alshehri; Abdulrahman A Albatly; Bert-Ram Sah; Christoph Schmid; Gerhard F Huber; Martin W Huellner
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

3.  Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism.

Authors:  Munro Peacock; John P Bilezikian; Preston S Klassen; Matthew D Guo; Stewart A Turner; Dolores Shoback
Journal:  J Clin Endocrinol Metab       Date:  2004-11-02       Impact factor: 5.958

4.  18F Fluorocholine PET/MR Imaging in Patients with Primary Hyperparathyroidism and Inconclusive Conventional Imaging: A Prospective Pilot Study.

Authors:  Wouter P Kluijfhout; Jesse D Pasternak; Jessica E Gosnell; Wen T Shen; Quan-Yang Duh; Menno R Vriens; Bart de Keizer; Thomas A Hope; Christine M Glastonbury; Miguel H Pampaloni; Insoo Suh
Journal:  Radiology       Date:  2017-01-25       Impact factor: 11.105

5.  Dual-Time-Point 18F-Fluorocholine PET/CT in Parathyroid Imaging.

Authors:  Wouter A M Broos; Maurits Wondergem; Friso M van der Zant; Remco J J Knol
Journal:  J Nucl Med       Date:  2019-03-15       Impact factor: 10.057

6.  Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism.

Authors:  Claudio Marcocci; Philippe Chanson; Dolores Shoback; John Bilezikian; Laureano Fernandez-Cruz; Jacques Orgiazzi; Christoph Henzen; Sunfa Cheng; Lulu Ren Sterling; John Lu; Munro Peacock
Journal:  J Clin Endocrinol Metab       Date:  2009-05-26       Impact factor: 5.958

Review 7.  Primary hyperparathyroidism.

Authors:  Marcella D Walker; Shonni J Silverberg
Journal:  Nat Rev Endocrinol       Date:  2017-09-08       Impact factor: 43.330

8.  18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature.

Authors:  Laura Evangelista; Ilaria Ravelli; Fabio Magnani; Maurizio Iacobone; Chiara Giraudo; Valentina Camozzi; Alessandro Spimpolo; Diego Cecchin
Journal:  Ann Nucl Med       Date:  2020-08-07       Impact factor: 2.668

9.  Added value of 18F-fluorocholine positron emission tomography-computed tomography in presurgical localization of hyperfunctioning parathyroid glands after dual tracer subtraction scintigraphy failure: A retrospective study of 47 patients.

Authors:  David Morland; Paul Lalire; Sophie Deguelte; Mohamad Zalzali; Capucine Richard; Sébastien Dejust; Camille Boulagnon; Sang Ly; Dimitri Papathanassiou; Brigitte Delemer
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

View more
  3 in total

1.  Multiglandular Parathyroid Disease in Primary Hyperparathyroidism With Inconclusive Conventional Imaging.

Authors:  K Zajíčková; J Včelák; Z Lešková; M Grega; D Goltzman; D Zogala
Journal:  Physiol Res       Date:  2022-04-11       Impact factor: 2.139

Review 2.  A Comprehensive Overview of the Parathyroid Tumor From the Past Two Decades: Machine Learning-Based Bibliometric Analysis.

Authors:  Zeyu Zhang; Fada Xia; Xinying Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

3.  Preoperative imaging in primary hyperparathyroidism: Are 11 C-Choline PET/CT and 99m Tc-MIBI/123 Iodide subtraction SPECT/CT interchangeable or do they supplement each other?

Authors:  Julie W Christensen; Afefah Ismail; Susanne B Søndergaard; Finn N Bennedbaek; Birte Nygaard; Lars T Jensen; Waldemar Trolle; Christoffer Holst-Hahn; Bo Zerahn; Bent Kristensen; Martin Krakauer
Journal:  Clin Endocrinol (Oxf)       Date:  2022-02-21       Impact factor: 3.523

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.